Alector, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Alector is a clinical-stage biopharmaceutical company developing immuno-neurology therapies for neurodegenerative diseases; it has no approved products and generated no product-sales revenue.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $56.2m | $79.9m | $72.8m | $104.3m |
| Research and development expense | $46.2m | $54.5m | $98.1m | $107.6m |
| General and administrative expense | $13.6m | $15.8m | $28.4m | $31.4m |
| Operating income (loss) | $(3.6)m | $9.5m | $(53.7)m | $(34.6)m |
| Net income (loss) | $1.4m | $9.9m | $(44.5)m | $(34.7)m |
| Operating cash flow | Not stated separately for the quarter | $(91.6)m | $77.6m |
Q2 net income included $6.4m of other income, primarily investment interest, and does not reflect operating profitability. Q2 net margin was approximately 2.4% (net income divided by collaboration revenue); the company reported an operating loss. Six-month net loss per share was $0.53, versus $0.42 in 2022.
At June 30, cash and cash equivalents were $131.5m and marketable securities were $498.5m, totaling $630.0m. Total assets were $708.7m; total liabilities $512.4m; stockholders’ equity $196.3m. The filing reports no borrowings; liabilities include deferred revenue, collaboration refund obligations, and lease liabilities. Deferred revenue was $313.9m. Refund liabilities to GSK totaled $122.6m ($21.4m current and $101.2m long-term). Six-month cash, cash equivalents, and restricted cash declined by $22.7m.
Changes versus the prior comparable period
- Q2 collaboration revenue fell $23.6m year over year; six-month revenue fell $31.6m. A major comparison factor was $68.9m of revenue recognized in Q2 2022 following termination of the AL003 program. In 2023, higher AL101 and AL002 revenue partly offset lower latozinemab revenue.
- Q2 operating expenses declined $10.6m year over year, mainly reflecting prioritization of later-stage programs, GSK cost-sharing credits, and lower general and administrative costs. AL002 direct R&D expense increased, while spending on latozinemab, AL101, and other programs declined.
- Other income increased $4.9m in Q2 and $9.8m for the six-month period, primarily due to higher yields on investments. Despite lower operating expenses, the six-month net loss widened by $9.7m.
- Operating cash flow shifted from $77.6m provided in the first half of 2022 to $91.6m used in the first half of 2023. The comparison was affected by a $95.7m increase in deferred revenue in 2022 versus a $49.3m decrease in 2023.
Outlook, management commentary, and risks
- Management expects current cash, cash equivalents, and investments to fund operations and capital expenditures through 2025, including multiple clinical milestones. This estimate depends on assumptions and could prove too optimistic; the company may seek additional financing.
- Priorities are latozinemab for FTD and AL002 and AL101 for Alzheimer’s disease. Management planned to complete enrollment in the INFRONT-3 Phase 3 trial of latozinemab in Q4 2023, with approximately 90–100 symptomatic participants treated for 96 weeks. It planned to complete INVOKE-2 enrollment in Q3 2023 and expected data in Q4 2024. GSK planned to initiate a global Phase 2 AL101 trial in early Alzheimer’s disease.
- The May 2023 GSK amendment made Alector responsible for funding and sharing development costs up to $140.5m for the initial AL101 Alzheimer’s Phase 2 trial. It reduced the GSK agreement’s transaction price from $700m to $571.6m and resulted in an estimated $128.4m refund liability. GSK milestone payments of up to $1.5bn remain potential, not assured.
- In February 2023, AbbVie amended its agreement; Alector received a $17.8m milestone for first-patient dosing in the AL002 long-term extension and may receive up to $12.5m for replacement-patient enrollment.
- Alector reduced its workforce by approximately 11% (about 30 employees) to prioritize late-stage programs. It recorded $1.9m of restructuring costs in the first half and expected about $0.1m more before year-end.
- A key clinical risk is treatment-emergent MRI findings resembling ARIA in the AL002 Alzheimer’s trial, including a small number of serious events. Alector stopped dosing and enrollment of APOE e4/e4 participants and continued enhanced MRI monitoring under an independent data monitoring committee.
- Other material risks include clinical-trial enrollment and efficacy uncertainty, dependence on GSK and AbbVie and third-party manufacturers, potential need for additional capital, and competition in neurodegenerative disease. Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter.
Investor verification priorities
- Check subsequent filings and trial updates against the stated INFRONT-3 enrollment and INVOKE-2 data timelines, and review the clinical safety and efficacy evidence, particularly the ARIA findings.
- Track actual cash burn and collaboration cost obligations, especially Alector’s capped AL101 trial funding, the GSK refund liability, and whether the through-2025 runway estimate remains supported.
- Reconcile collaboration revenue, deferred revenue, and partner cost-sharing adjustments; these materially affect reported revenue and period-to-period comparisons.
- Verify the status and terms of potential milestone payments from GSK and AbbVie; they are contingent and should not be treated as committed funding.
- Review progress after the workforce reduction and whether spending remains aligned with the prioritized programs and management’s financing assumptions.